文献速递胸部肿瘤

奥希替尼对比铂类-培美曲塞治疗EGFR T790M晚期NSCLC:AURA3总生存分析

Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
PubMed 文献 · Ann Oncol · 2020-08-27

AURA3研究最终总生存分析显示,在既往EGFR-TKI进展的EGFR T790M晚期NSCLC患者中,奥希替尼组与铂类-培美曲塞组的中位OS分别为26.8个月和22.5个月,HR为0.87(95%CI 0.67-1.12;P=0.277),差异无统计学意义,可能反映铂类-培美曲塞组高交叉率(73%)的影响。

要点

  • 奥希替尼组中位OS 26.8个月,铂类-培美曲塞组22.5个月,HR 0.87(P=0.277),无显著差异。
  • 铂类-培美曲塞组73%患者交叉至奥希替尼,交叉调整后HR为0.54(95%CI 0.18-1.6)。
  • 至首次后续治疗或死亡时间奥希替尼组显著更优(HR 0.21,P<0.001)。

核心结论

  • 在EGFR T790M晚期NSCLC患者中,奥希替尼对比铂类-培美曲塞未观察到统计学显著的OS获益,可能反映铂类-培美曲塞组高交叉率。

研究设计与样本

  • AURA3为随机、开放标签III期研究(NCT02151981),患者按2:1随机接受奥希替尼80mg每日一次口服或铂类-培美曲塞静脉化疗每3周一次(≤6周期)。
  • 共279例接受奥希替尼,140例接受铂类-培美曲塞(其中136例接受治疗),OS和安全性为次要终点。

主要发现

  • 数据截止时,奥希替尼组188例(67%)死亡,铂类-培美曲塞组93例(66%)死亡。
  • 奥希替尼组中位OS为26.8个月(95%CI 23.5-31.5),铂类-培美曲塞组为22.5个月(95%CI 20.2-28.8),HR为0.87(95%CI 0.67-1.12;P=0.277)。
  • 估计24个月和36个月生存率分别为奥希替尼组55%和37%,铂类-培美曲塞组43%和30%。
  • 交叉调整后HR为0.54(95%CI 0.18-1.6)。
  • 至首次后续治疗或死亡时间显示奥希替尼具有临床意义优势(HR 0.21,95%CI 0.16-0.28;P<0.001)。

关键数值与推荐

  • 奥希替尼组最常见可能与研究治疗相关的不良事件为腹泻(32%;≥3级1%)和皮疹(分组术语;32%;≥3级<1%)。
  • 铂类-培美曲塞组最常见可能与研究治疗相关的不良事件为恶心(47%;≥3级3%)。

临床怎么用

  • 对于既往EGFR-TKI进展的EGFR T790M晚期NSCLC患者,奥希替尼虽未显著改善OS,但至首次后续治疗或死亡时间显著更优,且安全性可管理。
  • 铂类-培美曲塞组高交叉率可能稀释OS获益,临床决策需综合考虑交叉治疗的影响。

局限性

  • 铂类-培美曲塞组高交叉率(73%)可能影响OS的统计效力及解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis. PATIENTS AND METHODS: Adult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum-pemetrexed) intravenously, every 3 weeks (≤6 cycles). Patients could crossover to osimertinib on progression confirmed by blinded independent central review. OS and safety were secondary end points. RESULTS: A total of 279 patients were randomly assigned to receive osimertinib and 140 to platinum-pemetrexed (136 received treatment). At data cut-off (DCO; 15 March 2019), 188 patients (67%) receiving osimertinib versus 93 (66%) receiving platinum-pemetrexed had died. The hazard ratio (HR) for OS was 0.87 [95% confidence interval (CI) 0.67-1.12; P = 0.277]; the median OS was 26.8 months (95% CI 23.5-31.5) versus 22.5 months (95% CI 20.2-28.8) for osimertinib and platinum-pemetrexed, respectively. The estimated 24- and 36-month survival was 55% versus 43% and 37% versus 30%, respectively. After crossover adjustment, there was an HR of 0.54 (95% CI 0.18-1.6). Time to first subsequent therapy or death showed a clinically meaningful advantage toward osimertinib (HR 0.21, 95% CI 0.16-0.28; P < 0.001). At DCO, 99/136 (73%) patients in the platinum-pemetrexed arm had crossed over to osimertinib, 66/99 (67%) of whom had died. The most common adverse events possibly related to study treatment were diarrhea (32%; grade ≥3, 1%) and rash (grouped term; 32%; grade ≥3, <1%) in the osimertinib arm, versus nausea (47%; grade ≥3, 3%) in the platinum-pemetrexed arm. CONCLUSIONS: In patients with T790M advanced NSCLC, no statistically significant benefit in OS was observed for osimertinib versus platinum-pemetrexed, which possibly reflects the high crossover rate of patients from platinum-pemetrexed to osimertinib. CLINICAL TRIALS NUMBER: ClinicalTrials.gov NCT02151981; https://clinicaltrials.gov/ct2/show/NCT02151981.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020. PMID: 32861806. doi:10.1016/j.annonc.2020.08.2100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。